GraceFinance · Source-backed public company research
Agomab Therapeutics NV (AGMB)
Nasdaq · Manufacturing · Biological Products, (No Diagnostic Substances)
Research deepening · 3/4 core data layers currently established
What Agomab Therapeutics NV does
A. History and Development of the Company We are a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. We have assembled an executive team with deep scientific and clinical development expertise and a track record of strong business leadership. Tim Knotnerus, our Chief Executive Officer, has extensive experience in corporate development and venture capital and previously held the position of Vice President of Corporate Development at AM-Pharma, where he and his team secured a $600.0 million option-to-buy deal with Pfizer.
Open the company story
The live GraceFinance page shows source-backed financial changes, management context, guidance, confirmed events, risks, and connected history only when the applicable evidence and relationships have been established. Missing research stays visible instead of being inferred.